secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profound Medical Corp. (PROF)
CIK:        0001628808
Form:       8-K
Filed at:   2026-08-06T20:20:20+00:00
Accession:  0001171843-26-005322
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Profound Medical Q2 revenue $2.5M (+12% YoY); net loss improves 39% to $9.5M; reiterates FY2026 guidance of $25M
--------------------------------------------------------------------------------

- Revenue $2.5M, up 12% YoY; $3.1M of TULSA shipments shifted to Q3 due to logistics, resolved.
- Net loss $9.5M ($0.26/share) vs $15.7M ($0.52/share) in Q2 2025, a 39% improvement.
- Gross margin 78% (up from 73%); operating expenses down 16% to $13.0M.
- Reiterates FY2026 revenue guidance of $25.0M (56% YoY growth) and gross margin ≥70%.
- TULSA-PRO installed base 84; payer coverage expanded by 18.3M lives; first employer health plans list TULSA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326005322/0001171843-26-005322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628808/000117184326005322/f8k_080626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer